Codexis, Inc.

CDXS Healthcare Biotechnology

Codexis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.4 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue fell 2.69%, EPS grew 18.8%, free cash flow grew 48.6% and total debt fell 14.1%, each against the same quarter a year earlier.

1.25 0.11 −8.09%
Market cap
$148.9M
P/E
0.0×
Fwd P/E
−6.6×
Dividend yield
—
F-score
4/9
Altman Z
−4.75
Beneish M
−3.57
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 4 5 5
ROE
(114.26%) (74.88%) (68.90%) (69.36%)
ROA
(47.00%) (29.63%) (24.77%) (23.79%)
ROIC
(195.29%) (218.36%) (100.87%) (151.17%)
Return on Tangible Assets
(89.16%) (52.03%) (41.34%) (50.94%)
Average Days of Receivables
52.43 52.86 35.46 34.33
Free Cash Flow per Share
(0.68) (0.27) (0.24) (0.13)
Free Cash Flow
(61.65) (23.84) (22.11) (12.16)
Capital Expenditures
(5.72) (4.47) (3.39) (1.76)
Other line items
Cash ROIC
(44.85%) (14.08%) (14.81%) (9.96%)
Accounts Receivable Turnover
5.11 5.70 8.98 6.90
Accounts Payable Turnover
3.30 4.25 2.12 4.95
Inventory Turnover
5.42 5.16 4.59 5.69
Average Days of Payables
80.84 60.74 89.55 94.44
Days of Inventory on Hand
64.54 71.02 84.20 57.99
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
99.53% 74.31% 65.07% 62.75%
Selling, General and Administrative Expense of Revenue
92.45% 66.88% 56.98% 55.50%
Share Based Compensation of Revenue
18.80% 13.67% 11.11% 9.94%
Interest Coverage
(8.30) (8.67) (5.68) (5.05)
Operating CF/Net income
0.87 0.44 0.59 0.34
Depreciation/Fixed assets
0.49 0.54 0.59 0.64
Capex/Depreciation
(0.84) (0.63) (0.45) (0.23)
Revenue per Share
0.59 0.81 0.86 0.85
Operating CF per Share
(0.62) (0.22) (0.21) (0.11)
Capex per Share
(0.06) (0.05) (0.04) (0.02)
Capex to Sales
0.11 0.06 0.04 0.02

Fold the line items

Columns are period end dates